Important changes to US prescribing information for efavirenz
5 February 2007. Related: Antiretrovirals.
Antiretrovirals
Changes to US product label for T-20 (enfuvirtide)
5 February 2007. Related: Antiretrovirals.
Explanation for failure of TMC-125 (etravirine) in TMC227 study
6 December 2006. Related: Conference reports, Antiretrovirals.
Saquinavir/r vs lopinavir/r: interim results from the Gemini study
6 December 2006. Related: Conference reports, Antiretrovirals.
TMC 114 recommended for conditional approval in Europe
6 December 2006. Related: Antiretrovirals.
Atazanavir 300mg capsule approved in US
6 December 2006. Related: Antiretrovirals.
Lipid profile of integrase inhibitor MK-0518: 24 week results compared to efavirenz in treatment naive patients
7 October 2006. Related: Conference reports, Antiretrovirals.
NRTI elvucitabine active against HIV in a 7-day monotherapy study
7 October 2006. Related: Conference reports, Antiretrovirals.
Efavirenz/tenofovir fails as 2-drug maintenance regimen
7 October 2006. Related: Conference reports, Antiretrovirals.
Early access programme for MK-0518 integrase inhibitor
7 October 2006. Related: Antiretrovirals.
Etravirine (TMC-125) available on named patient programme in the UK
7 October 2006. Related: Antiretrovirals.
Fixed dose combination (FDC) of tenofovir/FTC/efavirenz (Atripla) filed in EU
7 October 2006. Related: Antiretrovirals.
Tipranavir available in Scotland – almost one year after EU approval
7 October 2006. Related: Antiretrovirals.
FDA decision delayed on Biojector for administering T-20 pending additional safety information
7 October 2006. Related: Antiretrovirals.
Integrase inhibitor MK-0518: early results show greater early potency than efavirenz
10 September 2006. Related: Conference reports, Antiretrovirals.
Maraviroc results in R5/X4 mixed/dual tropic patients: unexpected safety data shows possible immunolocical effect
10 September 2006. Related: Conference reports, Antiretrovirals.
Vicriviroc 24-week results in triple-class experienced R5-tropic patients
10 September 2006. Related: Conference reports, Antiretrovirals.
Etravirine (TMC-125) associated with -1 log viral load reduction at 48-weeks results in treatment experienced patients
9 September 2006. Related: Conference reports, Antiretrovirals.
Three-class experienced patients experience 1 log viral load reduction using monoclonal antibody TNX-355
9 September 2006. Related: Conference reports, Antiretrovirals.
New data on darunavir (TMC-114)
9 September 2006. Related: Conference reports, Antiretrovirals.
Lopinavir/r monotherapy: less potent than triple therapy with higher risk of resistance
9 September 2006. Related: Conference reports, Antiretrovirals.
Atazanavir/r monotherapy and CNS penetration
9 September 2006. Related: Conference reports, Antiretrovirals.
Fosamprenavir/r is non-inferior to Kaletra in treatment naive patients
9 September 2006. Related: Conference reports, Antiretrovirals.
Tenofovir/FTC maintains greater virological response and reduced lipoatrophy compared to AZT/3TC after 96 weeks
9 September 2006. Related: Conference reports, Antiretrovirals.
Antiretroviral effect of foscarnet in patients with multiple drug resistance in late stage HIV disease
9 September 2006. Related: Antiretrovirals.
New formulation of lopinavir/r approved in Europe (Kaletra) and new tradename for access countries (Aluvia)
3 August 2006. Related: Antiretrovirals.
US approval for darunavir (TMC-114, Prezista)
3 August 2006. Related: Antiretrovirals.
Boehringer stops tipranavir trial in treatment-naive patients
3 August 2006. Related: Antiretrovirals.
FDA approves fixed-dose combination of efavirenz/tenofovir/FTC (Atripla): joint company collaboration produces once-daily one pill combination
3 August 2006. Related: Antiretrovirals.
Evidence that CCR5 is protective against West Nile virus: implications for CCR5 inhibitors
3 August 2006. Related: Antiretrovirals.
Efavirenz levels above recommended upper target in 20% of African patients in Senegal
11 June 2006. Related: Conference reports, Antiretrovirals.
Lower dose of AZT provides adequate exposure in patients with low body weight
11 June 2006. Related: Conference reports, Antiretrovirals.
Fixed-dose formulation of efavirenz/tenofovir/FTC bioequivalent to separate dosing
10 June 2006. Related: Conference reports, Antiretrovirals.
Saquinavir/r (1000/100mg) levels reduced when taken fasted and should be taken with food
10 June 2006. Related: Conference reports, Antiretrovirals.
Lack of food effect with Meltrex formulation of lopinavir/r
10 June 2006. Related: Conference reports, Antiretrovirals.
Food interaction reduces ddI intracellular absorption and supports requirement to take fasted
10 June 2006. Related: Conference reports, Antiretrovirals.
Conflicting results on how T-20 affects tipranavir
10 June 2006. Related: Conference reports, Antiretrovirals.
Development of d-d4FC (dexelvucitabine, Reverset) discontinued
12 May 2006. Related: Antiretrovirals.
Other new antiretrovirals at Denver: the future seems bright
12 April 2006. Related: Conference reports, Antiretrovirals.
Early integrase inhibitor studies in treatment experienced patients raise hopes for new drugs in a new class
25 March 2006. Related: Conference reports, Antiretrovirals.
Atazanavir in treatment naive patients, with and without ritonavir boosting
25 March 2006. Related: Conference reports, Antiretrovirals.
CNS penetration of ARV drugs is associated with lower CSF viral load
25 March 2006. Related: Conference reports, Antiretrovirals.
Metrex formulation of Kaletra available on named patient access in UK
10 March 2006. Related: Antiretrovirals.
Treatment-naive trial of tipranavir discontinues highest dose arm
8 March 2006. Related: Antiretrovirals.
FTC studies at EACS: reduced incidence of M184V compared to 3TC; side effect profile in clinical practice
11 February 2006. Related: Conference reports, Antiretrovirals.
Efficacy of lopinavir/r in patients with advanced HIV (CD4 <25 cells/mm3)
11 February 2006. Related: Conference reports, Antiretrovirals.
Potential barriers to use of T-20: results from patient and physician interviews
11 February 2006. Related: Conference reports, Antiretrovirals.
Clinical experience of switching to atazanavir in the UKs largest clinic
11 February 2006. Related: Conference reports, Antiretrovirals.
Replacing a PI with atazanavir: separating swans from ducklings?
11 February 2006. Related: Conference reports, Antiretrovirals.
TMC 125: some good and bad news
11 February 2006. Related: Conference reports, Antiretrovirals.
When to change a failing regimen: second-line and salvage strategies
11 February 2006. Related: Conference reports, Antiretrovirals.
Antiretrovirals and other stuff!
11 February 2006. Related: Conference reports, Antiretrovirals.
Understanding TMC114 power against resistant HIV
10 February 2006. Related: Conference reports, Antiretrovirals.
New antiretroviral compounds at ICAAC: new PI brecanavir from GSK; maturation inhibitor PA-457; antiviral activity of monoclonal antibody; TNX-355 in treatment experienced patients
10 February 2006. Related: Conference reports, Antiretrovirals.
Three measures confirm 144-week renal record of tenofovir
10 February 2006. Related: Conference reports, Antiretrovirals.
Low rash risk with efavirenz after nevirapine rash
10 February 2006. Related: Conference reports, Antiretrovirals.
SMART study halted due to safety concerns with significantly more AIDS events in the treatment interruption arm
9 February 2006. Related: Antiretrovirals.
TMC114 (darunavir) new drug applications submitted to US and European regulatory agencies
9 February 2006. Related: Antiretrovirals.
Named-patient access programme available in UK for new protease inhibitor darunavir (TMC114)
13 December 2005. Related: Antiretrovirals.
Tibotec discontinues TMC125 study C227: phase III studies continue
13 December 2005. Related: Antiretrovirals.
New Kaletra tablet formulation (meltrex) approved by FDA
13 December 2005. Related: Antiretrovirals.
GSK closes phase 3 studies of its CCR5 inhibitor aplaviroc and terminates development programme
13 December 2005. Related: Antiretrovirals.
Schering discontinues phase 2 studies of vicriviroc in treatment naive patients
13 December 2005. Related: Antiretrovirals.
FDA issues approvable letter for Bioject needle-free injection device
13 December 2005. Related: Antiretrovirals.
Improved clinical outcome in 80% patients who modified an NNRTI or PI dose following therapeutic drug monitoring (TDM)
13 December 2005. Related: Antiretrovirals, Treatment strategies.